StockNews.AI
ALT
StockNews.AI
180 days

Altimmune to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on February 27, 2025

1. Altimmune to report Q4 and full-year 2024 financial results on Feb 27. 2. Conference call set at 8:30 AM ET via webcast on the IR website. 3. Call will cover detailed financial performance and a broader business update. 4. Company focuses on next-generation peptide-based therapeutics for obesity and MASH.

3m saved
Insight
Article

FAQ

Why Neutral?

This is a standard earnings release notification. Historically, such announcements generate minimal immediate price movement until actual results are disclosed.

How important is it?

Earnings announcements typically affect short-term trading sentiment. Without specific results, the impact remains moderate but significant for immediate reactions.

Why Short Term?

Immediate market reaction is expected post-results; long-term impact will depend on the actual figures. Past earnings reports have driven short-term volatility until trends become clear.

Related Companies

February 20, 2025 07:30 ET  | Source: Altimmune, Inc GAITHERSBURG, Md., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its fourth quarter and full year 2024 financial results on Thursday, February 27, 2025. Altimmune management will host a conference call at 8:30 am E.T. on February 27 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune’s Investor Relations website at https://ir.altimmune.com/investors. Participants who would like to join the call may register here to receive the dial-in numbers and unique PIN to access the call. Shortly after the call, a replay will be available on the Investor Relations website for up to three months. About Altimmune Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH. For more information, please visit www.altimmune.com. Follow @Altimmune, Inc. on LinkedInFollow @AltimmuneInc on Twitter Company Contact:Greg WeaverChief Financial OfficerPhone: 240-654-1450ir@altimmune.com Investor Contact:Lee RothBurns McClellanPhone: 646-382-3403lroth@burnsmc.com Media Contact:Danielle CanteyInizio Evoke, BiotechPhone: 619-826-4657Danielle.cantey@inizioevoke.com This press release was published by a CLEAR® Verified individual.

Related News